ImageneBio Inc (IMA) Gagner

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.